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ABSTRACT Cell-surface glycoproteins of 96 kDa (gp96)
have been implicated in immunogenicity of methylcholan-
threne-induced mouse sarcomas in syngeneic hosts. In view of
the potential immunogenicity of gp96-related molecules in
human tumors, we have defined the 5'-regulatory and complete
coding regions of a human gp96 transcript. The 5'-regulatory
region contains an imperfect heat shock element apart from
other regulatory sequences. The amino acid sequence ofhuman
gp96 is 96% homologous to its murine counterpart and genes
for the two molecules show significant homology between
untranslated regions. Comparison of gp96 sequences to other
sequences in DNA and protein data bases indicates significant
homology with the stress proteins 94-kDa glucose-regulated
protein (grp94) and 108-kDa heat shock protein (hsplO8) and
99-kDa endoplasmic reticular protein (ERp99). These mole-
cules are either identical or represent a family of closely related
molecules. With regard to their role in tumor immunity, it
needs to be determined whether gp96 molecules are tumor
antigens per se or whether they serve as carriers of other
immunogenic moieties.
Structural identification of tumor antigens that can elicit
tumor rejection in the host of origin is the central aim oftumor
immunology. In animal systems, the immunogenicity of such
antigens can be monitored in vivo by tumor transplantation
assays, and progress has been made in defining antigens that
elicit transplantation immunity in several mouse and rat
tumors (1-3). In contrast, immunological analysis of human
cancer is limited in the main to the study of humoral and
cellular antitumor responses that can be demonstrated in
vitro. Melanoma has been extensively studied in this regard
and antibodies with apparent specificity for autologous mel-
anoma cells have been found in a small proportion of patients
with melanoma (4). Specific T-cell responses to melanoma
cells have also been reported by a number of laboratories
using interleukin 2-dependent T-cell cloning (5-10). One of
the serologically defined human tumor antigens has been
partially characterized (11), but identification of T-cell-
defined human melanoma antigens has remained elusive.
Boon and his colleagues (12) have described an approach for
identifying T-cell recognized epitopes on mouse tumors. This
method, involving transfection and molecular cloning, shows
much promise for the comparable analysis of human tumor
antigens defined by T cells.
Immunogenicity of chemically induced sarcomas of inbred
mice has received the greatest attention in experimental
systems. These tumors elicit immunity to large challenges
and display extensive diversity-i.e., each tumor in a given
mouse strain appears to have its own individually distinct
antigenicity. We have previously shown that 96-kDa cell-
surface glycoproteins (gp96) derived from two antigenically
distinct BALB/c mouse sarcomas (Meth A and CMS5) elicit
resistance to tumor transplants; Meth A gp96 elicits resis-
tance to Meth A but not CMS5, and CMS5 gp96 elicits
resistance to CMS5 but not Meth A (13). cDNA clones
encoding gp96 from these chemically induced tumors and
from mouse spleen have been isolated and sequenced (1, 14).
No structural changes have been detected in tumor-derived
gp96. Rabbit antisera to murine gp96 detect cross-reactive
gp96 molecules in human and rat tissues, indicating that
gp96-related molecules are widely distributed and phyloge-
netically conserved (ref. 15; unpublished data). In the present
study, the human counterpart of murine gp96 has been
defined by cDNA and genomic cloning.¶
MATERIALS AND METHODS
DNA and RNA Extraction: Southern and Northern Blot
Analysis. Genomic DNA preparations from human tumor cell
lines, total cellular RNA and poly(A)+ RNA isolation, and
Northern and Southern blotting were performed as described
(16). RNA probes were prepared by T3 or T7 promoter-
driven transcription in plasmid pT3-T7-18 or pT3-T7-19 (Life
Technologies, Bethesda, MD).
cDNA Library Construction and Screening. The library
LASTD2 was constructed from human teratocarcinoma
cDNA in the vector Charon BS(-) (17). DNA from positive
clones was digested with the restriction enzyme Not I, heat
inactivated, diluted 1:5 with water, and buffer (final concen-
trations, 50 mM Tris-HCl, pH 7.6/10 mM MgCl2/1 mM
ATP/1 mM dithiothreitol/5% polyethylene glycol 8000) and
1 Weiss unit of T4 DNA ligase were added directly. Aliquots
of this mixture were used to transform Escherichia coli
strains LE392 or DH5a.
Sequencing. Sequencing was performed on small-scale
preparations of plasmid DNA or on single-stranded DNA
derived from R408 helper phage superinfection (18) of plas-
mid-bearing E. coli NM522 by dideoxynucleotide sequencing
using modified T7 DNA polymerase or Thermus aquaticus
DNA polymerase according to the manufacturers' instruc-
tions. In addition, a partial set of deletion subclones was
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constructed for sequencing from both the 5' and 3' ends of the
clone by the Exo III/mung bean nuclease method (19).
Primer-Extension Analysis. Primer-extension reactions us-
ing 40,000 cpm of end-labeled oligonucleotide were per-
formed with yeast tRNA, total cytoplasmic human RNA, and
poly(A)+ human RNA as described (16).
RESULTS
Derivation and Characterization of gp96 cDNA Clones.
Approximately 1,000,000 clones from cDNA library
LASTD2 were probed with the murine gp96 cDNA probe
Asex6. Nineteen positive phagemid clones were purified; two
phagemids with the largest inserts were subcloned, yielding
the plasmids pH48 and pH52. Fig. 1 is a composite derived
from pH48 and pH52 and indicates an open reading frame
encoding a potential 803-amino acid 92,450-Da protein with a
predicted pI of 4.54. Hydropathicity analysis of pH48, aver-
aging over a six-residue window (21), demonstrates an 18- to
19-residue N-terminal hydrophobic region, presumably en-
coding a signal peptide. Methods predicting signal peptide
cleavage (22) indicate that the two most likely sites for
cleavage lie after the 17th and 21st residues. The human gp96
signal peptide is therefore provisionally defined as containing
21 amino acids, corresponding to the signal peptide cleavage
site in mouse gp96 (14). The mature 782-amino acid protein
has a predicted molecular mass of 90,170 Da.
pH48/52 contains a 5' untranslated region [nucleotides (nt)
13-105], translation initiation codon ATG (nt 106-108), signal
peptide (nt 106-168), five potential N-linked glycosylation
sites (starting at nt 424, 754, 1438, 1546, and 1609), a TAA
5'
stop codon (nt 2515-2517), 3' untranslated region (nt 2518-
2780), polyadenylylation signal (nt 2762-2767), and a 12-
base-pair (bp) poly(A) tail (attached to nt 2780). A sequence
putatively involved in destabilizing mRNA (23) is found twice
in the 3' untranslated region (starting at nt 2563 and 2717).
The amino acid sequence KDEL is located at the C terminus
of the open reading frame.
gp96 Transcripts in Human Tumor Cells. Different amounts
of gp96 transcripts are present in various amounts in a range
of human tumor cell lines. The human gp96 transcript is =z2.8
kilobases (kb) long, which is also the size of the mouse gp96
transcript. In a series of >30 cell lines of various histological
origins, no tumor cell line was found lacking gp96 transcripts.
Southern Blot Analysis of Human Genomic DNA with gp96
cDNA pH48. Human genomic DNA derived from tumor cell
lines was digested with several restriction enzymes and probed
with fragments derived from pH48. As shown in Fig. 2, digests
of DNA from neuroblastoma cell line LA-1-lSn with seven
restriction enzymes yielded three or four hybridizing bands
using 5' or 3' probes from pH48. Multiple hybridizing bands
were also observed with genomic DNA derived from other
human cell lines. These data suggest that there are three or four
gp96-related genes per haploid human genome. Four tumor-
derived cell lines and two peripheral blood lymphocyte spec-
imens were tested by Southern blot analysis; no gross differ-
ences in restriction pattern with seven restriction enzymes
were observed with 5' and 3' pH48 probes.
Analysis of gp96 Transcription Start Site. Fig. 3 represents
a primer-extension analysis of HeLa mRNA with an anti-
sense oligonucleotide (nt 58-93 of the sequence in Fig. 1).
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M R A L W V L G L C C V L L T
[+1]
F G S V R A D D E V D V D G T V E E D L G K S R E G S R T D D E V V Q R E E E A I Q L D G L N A S Q
TTCGGGTCGGTCAGAGCTGACGATGAAGTTGATGTGGATGGTACAGTAGAAGAGGATCTGGGTAAAAGTAGAGAAGGATCAAGGACGGATGATGAAGTAGTACAGAGAGAGGAAGAAGCTATTCAGTTGGATGGATTAAATGCATCACAA 30 0
50'3
I R E L R E K S E K F A F Q A E V N R M M K L I I N S L Y K N K E I F L R E L I S N A S D A L D K I
ATAAGAGAACTTAGAGAGAAGTCGGAAAAGTTTGCCTTCCAAGCCGAAGTTAACAGAATGATGAAACTTATCATCAATTCATTGTATAAAAATAAAGAGATTTTCCTGAGAGAACTGATTTCAAATGCTTCTGATGCTTTAGATAAGATA 450
[100]
R L I S L T D E N A L S G N E E L T V K I K C D K E K N L L H V T D T G V G M T R E E L V K N L G T
AGGCTAATATCACTGACTGATGAAAATGCTCTTTCTGGAAATGAGGAACTAACAGTCAAAATTAAGTGTGATAAGGAGAAGAACCTGCTGCATGTCACAGACACCGGTGTAGGAATGACCAGAGAAGAGTTGGTTAAAAACCTTGGTACC 60 0
(150]
I A K S G T S E F L N K M T E A Q E D G Q S T S E L I G Q F G V G F Y S A F L V A D K V I V T S K H
ATAGCCAAATCTGGGACAAGCGAGTTTTTAAACAAAATGACTGAAGCACAGGAAGATGGC CAGTCAACTTCTGAATTGATTGGCCAGTTTGGTGTCGGTTTCTATTC CGCCTTCCTTGTAGCAGATAAGGTTATTGTCAC TTCAAAAC-AC 750
2__[200]
N N D T Q H I W E S D S N E F S V I A D P R G N T L G R G T T I T L V L K E E A S D Y L E L D T I K
AACAACGATACCCAG CACATCTGGGAGTCTGACTCCAATGAATTTTC TGTAATTGCTGACCCAAGAGGAAACAC TCTAGGACGGGGAACGACAATTACCCTTGTCTTAAAAGAAGAAGCATCTGATTAC CTTGAATTGGATACAATTAAA 90 0
[250]
N L V K K Y S Q F I N F P I Y V W S S K T E T V E E P M E E E E A A K E E K E E S D D E A A V E
AATCTCGTCAAAAAATATTCACAGTTCATAAACTTTCC TATTTA7'GATGGAGCAGCAAGACT-GAAACTlGTTGAGGAG CCCATGGAGGAAGAAGAAG CAGCCAAAGAAGAGAAAGAAGAATCTGATGATGAAGC TGCAGTAGAGDGAAGAA1050
[3010
E E E R K P K T X X V E R T V W D W E L M N D I K P I W Q R P S K E V F E D E Y R A F Y K S F S R E
GAAGAAGAAAAGAAACCAAAGACTAAAAAAGTTGAAAAAAC 1TCTCGGACTGGGAACTTATGAATGAACAAACCCAATATGCAGAGAC2CACAAAAGAACTAGAAGAAGATGAATACAAAGCTTTCTACAAATCATTTTCAAAGAA12CC
[3531
S D D P M A Y I H F T A E G E V T I K S I L F V P T S A P R G L F D E Y G S K K S D Y I K L Y V R R
AGTGATGACCCCATGGC:TATATTCACTTTACTGC:GAAGGGGDAAGTTACCTDDCAAA-CAATTTTATDDTTACCCACA-CDGC--CCACDDDCDDD DDDGACDAADTADGGATC.AAAAAGAGCGA.TAACA-TAAGCDTCATDDGCCDDC1 35D
[4 0 0
V F I T D D F H D M M P R Y L N F V K G V V D S D1 L P L N V S R EI L Q Q H K L L K V I R K K _ V
GTATTCATCACAGACGAC-TTCCATGA7-ATGA-GC CTAAATA CC--AATTTTGT_ AAGGGTGTGG-GGAC-TCAGAT-IATC7C&CCCTTGAA- GTTTCCCGCcAGACTCT.TCAG~CAACATAAAC TG-TTAAGGTGATTAGGAAGAAGCT-TG7T ;5 0 0
R K T L D M I K K I A D D K Y N D T F W K E F G T N 7K L G V D H S N R T R L A K L L R F Q S S
CDTAAAACGCTGGACATGATCAAGA.AGATTG TGATGA AAATACAA- GATAC-RTTTGGAAAGAATTTGGTACCAA-A-CAAGCTI-GGTGDGATTGAAGACCACT-GAArCGAACACGTCTTGCTAAACTTCTAGGTTCCAGTT CT 1650
[III]
H H P T D I T S L D Q Y V IR M K E R Q D E Y F M- A G S S R IE A E S S P F V E R L L K X G Y E V
CADCATCCAACTGACATTACTAGSCCTAGACCAGTATG-GGAAAGAADGAAAGGADNAAACAAGACAAAATCTACDT-CADGGCCD-GG .CCASCAGAAAAGAGCTGAATCT-CDTCCCATTCTGTTGAGCGACTCDTGAAA.AtAGGGCTATCAAGTT C8R1
[55C],
I Y L T E P V D E Y C I Q A L P E F D GD R F Q N V A K IG V K F D E S E K TD E S R E A V E K E F
ATT; ACCTCACAGAACCTGTGGATGAAT.ACTGTATTCAGGCCC. TCCCGAATTTGATGGGAAGAGGTTCCAGAATGTTGCCAAGGAAGGAG-GAAGT-- GATGAPAGTGAGA-kAACTAAGGAGAG-C GTGAAGCAGT7GAGAAAGAATTT l195 0
[615]0
E P L L N W M K D X A L K D K I E K A V V S Q R L T E S P C A L V A S O Y G D S G N M r R I M K A Q
GAGCCTCTGCTGAATTGGATGAAAGATAAAGCCCTTAAGGACAAGATTGAAAAGGCTGTGGTGTCTCAGCGCCTGACAGAATCTCCGTGTGCTTTGGTGGCCAGCCAGTACGGATGGTCTGGCAACATGGAGAGAATCATGAAAGCACAA 2 1 0 0
[650]
A Y Q T C K D I S T N Y Y A S QO K T F E I N P R H P L I R D M L R R I K E D E D D K T V L D L A V
GCGTACCAAACGGGCAAGGACATCTCTACAAATTACTATGCGAGTCAGAAGAAAACATTTGAAATTAAT'CtCAGACA'CCCGCTGATCAGAGACATGC TTCGACGAATTAAGGAAGATGAAGATGATAAAACAGTTTTG GATCTTGCTGTG 2 2 5 0
[750]l
V L F E T A T L R S G Y L L P D T K A Y G D R I E R M L R L S L N I D P D A K V E E E P E E E P E E
GTTTTGTTTGAAACAGCAACGCTTCGGTCAGGGTATCTTTTACCAGACACTAAAGCATATGGAGATAGAATAGAAAGAATG CTTCGCCTCAGTTTGAACATTGAC CCTGATGCAAAGGTGGAAGAAGAGCCCGAAGAAGAACCTGAAGAG 22400
[75 _
T A E D T T E D T E Q D E D E E M D V G T D E E E E T A K E S T A E K D E L
I.-I-1--l---~~~~------ I- --------- --- ----- ----- ----- -1- - ---- - .
AATGTAAATTTGTACTAITTAACTGACTATTCTTGATGTAAAATCTTGTCATGTGTATAAATAAAAGATCCCAAAT
3'
; 2550
; 2700
2780
FIG. 1. Complete sequence of the human gp96 transcript derived from pR8 (nt 1-12) and pH48/52 (nt 13-2780). Residue +1 is the site of
transcription initiation. Other features include ribosomal binding site/translation start site (20) (double underlined), 21-amino acid signal peptide
(overlined), N-linked glycosylation sites Asn-Xaa-Ser/Thr (NXS/T, overlined), potential transmembrane region (overlined), Lys-Asp-Glu-Leu
endoplasmic reticular retention sequence (KDEL, overlined), ATTTA mRNA destabilization signals (underlined), and AATAAA poly(A)
addition signal (underlined). A 12-residue poly(A) tail (not shown) is found after nt 2780.
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FIG. 2. Southern blot analysis of human neuroblastoma cell line
LA-1-15n genomic DNA. Fifteen micrograms of total genomic DNA
was digested with the indicated restriction enzymes and electropho-
resed over 0.8% agarose, blotted, and hybridized 16 hr to random
32P-labeled DNA probe pH48AG (3' 314 bp of pH48 cDNA) at 60TC.
An autoradiogram exposed for 3 days with two intensifying screens
is shown. Molecular size markers are indicated as bars to the right
(top to bottom): 23.1, 9.4, 6.6, 4.4, 2.3, 2.0, 1.35, 1.1, 0.9, and 0.6 kb.
B, BamHI; E, EcoRI; H, HindIII; P, Pst I; Pv, Pvu II; S, Sst I; X,
Xba I.
The major visible band indicates that the mature mRNA is
initiated 57 bp from the primer 3' terminus. This places the
start of transcription 12 bp upstream of the first base of the
cDNA clone pH48. The sequence of this region was deter-
mined by analysis of a genomic clone pR8, discussed below,
which represents the 5' end of the coding gp96 gene.
Sequencing of gp96 Genomic Clone pR8. Genomic clones
hybridizing to a probe for the 5' end of pH48 were isolated
from a peripheral blood lymphocyte DNA library. One
genomic clone was digested with EcoRI and subcloned into
pBluescriptII KS(-). Subclone pR8 contained the 5' coding
region ofpH48 and its sequence was determined by using the
oligonucleotide (nt 58-93) used for primer extension. One
CCAAT box (nt -195), five inverted CCAAT boxes (nt
-300, -220, -141, -107, and -76), and one consensus Ap2
site (nt -442) (Fig. 4) are observed upstream of the tran-
scription start site. In addition, a consensus site for one of
several factors that bind to the E4 promoter of adenovirus
(E4TFI) is found at nt -41. Five consensus Spl sites (nt
-571, -272, -258, -129, -50) are evident within the 800
bases upstream of the transcription start site, and an addi-
tional Spl site is observed in the 5' untranslated region at nt
+3. One imperfect heat shock transcriptional control element
(HSE) is located upstream of the start of transcription (nt
-118), showing a 6/8-bp match with consensus sequence
CNNGAANNTTCNNG. Another weak HSE is seen in in-
tron I (nt 206). A TATA box is observed 32 bases upstream
of the start of transcription, but it differs significantly in
sequence from the consensus TATAAA.
The putative gp96 promoter and first exon are rich in G and
C nucleotides (59.8%) and CpG dinucleotides; the ratio of
CpG to GpC dinucleotides in this region is 0.94, defining the
region immediately 5' to the start of transcription as a CpG
"island" (24). In addition, several Spl sites are observed in
this region. These structural features characterize other
constitutively expressed genes (25, 26).
Comparison of Murine and Human gp96: Homology with
Stress-Induced Proteins. Human and murine gp96 show 96%
1 2 3 4
FIG. 3. Primer-extension analysis of HeLa RNA using 36-mer
antisense oligonucleotide (nt 58-93) of Fig. 1. y-_32P-end-labeled
oligonucleotide (40,000 cpm) was hybridized overnight to 10 ,g of
yeast tRNA (lane 2), total cytoplasmic HeLa RNA (lane 3), twice
enriched poly(A)+ HeLa RNA (lane 4), or not hybridized (lane 1)
before primer extension and electrophoresis on a 6% polyacrylamide
sequencing gel. The major extension product (arrow) is observed 57
bases from the end of the primer, although other species are also
visible.
homology at the amino acid level and 90% homology at the
DNA sequence level. Of the 25 differences in the amino acid
sequences, 18 (72%) are conservative changes. Similarly, of
the 190 differences at the nucleotide level, 161 (85%) occur in
the third base of a codon. In contrast to the strong conser-
vation of coding regions, the first four introns of the two
genes show much less homology (unpublished data). In
relationship to other highly conserved proteins, mouse and
human gp96 have a higher degree of homology than a-
hemoglobin (80%), histone H3 (87%), or cytochrome c (91%),
although they are less conserved than a-tubulin (>99%) or
skeletal muscle actin (100%).
Comparison ofgp96 with other sequences in the data bases
shows homologies with stress-induced or heat shock proteins
hspl00 (27) and hsp90 (28). At the amino acid level, >90%
homology is observed between gp96 and hspl00, and 50%
between gp96 and hsp90. In addition to homologies in the
coding region, homologous regions are also observed be-
tween human gp96, grp94 (glucose-regulated protein), and
chicken hsplO8 promoters (ref. 29; Fig. 4). There is also a
homology, noted previously, with the endoplasmic reticular
protein ERp99 (30). Coding regions of hsp70 and other stress
proteins do not show significant homology with gp96.
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5' ACAATGGAGATCCTGGAATAGGCACATATCTCTACGTAATCAGAACGAGATGTAACAT CA CTCTGGCAAAGACACGCTGGGGGAA -701
Spi
CGTGAAGAAAGGGCCAAAACTACGCAGCTGGTCCTCAGGACAAGCTACGACCCCCAGCATTCAATGCAGTGAA CCAGATGCATGCCGGGAGCTGTAGTTTCATCACCACCGCCACCCCCCGCCCCCCC
Ap2
GCCATCTGAAAGCGTTCTAGGGGATTTGCAACCTCTCTCGTGTGTTTCTTCTTTCCGAGAAGCGCCGTGGCCGCGAAAGTCGTGCTGGAATCACTTCCAACC
CrF
.4-
GGTGAAGAACACGTTGCCATGGCTACCGTTTCCCCGGTCACGGAATAAACGCTCTCTAGGATCCGGAAGTAGTTCCGCCGCGACCTCTCTAAAAGGATGGATGTGTTCTCTGCTTACATTCATTGGACGTTTTCCCTTAG
Spi Spi ClF C1F
AC.GGM CCCAAGC-C GCGCC.GTCCCACGTGTGAGGGGCCCGCGGAGCCATTTATT1GAAGT ACCTCATGAG GCC TCGGGCATCGGTCACCGCACCTGGACAGCTCCG
CTF SpO HSE ClF CIT Spi E4TFI
ATTGGTGGACTT CNTCTGTTCCGTC _GCTGCGTGTA
(Spi) M R A L W V L G L C C V
aiTGGGO GGACCGCGCGGCTGGAGG _ TGCGATCGAAGGGGACTTGAGACTCCGCGACGCTAGCCTGTGGGTGCTGGGCCTCTGCTGCGT
L L T F (G) Intron I HSE
CCTGCTGACCTTCG[GTGAGTGATCrIGcAACTGGGAGGGGGGATCCCGGGGCCTGCGTGCCA
TCCTCGAAAGAGGGCAAGGGTTACGTTTATTCTCTTCTTCCTCTGGAAATAAAAAAAGAGAGC AACATCATCTAACTGCCCTACAGATCTAATAGTATCTC. ... 3'
-561
-421
-281
-141
-1
140
279
382
FIG. 4. Partial sequence of genomic clone pR8 encoding the 5' region of a human gp96 gene and promoter. Features include possible
transcription factor binding sites (overlined with name of factor), transcription start site (base + 1, underlined), imperfect heat shock element
(HSE) (nt -118 to -105 and nt 206-219, double underlined), atypical TATA box (double overline), translation start site and exon 1 (heavy
underline), 5' region of intron I (in brackets), and conserved regions between chicken hspi08, human grp94, and human gp96 (dashed underline
with double-headed arrows).
DISCUSSION
Several gp96-related genes have now been found in both mice
and humans. Short probes derived from different regions of
human gp96 cDNA hybridize with as many as four bands on
Southern bands of human genomic DNA digested with a
number of restriction enzymes, and human gp96 genes map
to at least two different chromosomes (unpublished data).
gp96 cDNA clones derived from a human tumor have been
used to analyze one of these genes and its associated tran-
script.
Organization of the 5'-regulatory region of human gp96
provides some clues to the apparently constitutive nature of
gp96 expression. Housekeeping genes are generally associ-
ated with unmethylated CpG islands encompassing the site of
transcription initiation. CpG islands can be activated regard-
less of their site of methylation by some transcription factors
(e.g., Spl; ref. 31) and lack ofCpG methylation is presumably
maintained by binding of such factors. The 5'-regulatory
region and exon 1 of human gp96 represent a CpG island
containing six Spl binding sites. The atypical TATA box of
human gp96 and heterogeneity of transcription initiation as
determined by primer extension are common features in
other housekeeping genes (25, 26). The 5' upstream region
contains several other consensus transcriptional factor bind-
ing sites, including a CCAAT box, five inverted CCAAT
boxes, and one Ap2 site; the CCAAT box is not generally
observed in promoters of constitutively expressed genes.
Structure and function of a similar promoter (human grp94)
have been demonstrated by Chang et al. (29).
The longest open reading frame of the human gp96 tran-
script contains a 5' signal peptide-encoding region and five
potential N-linked glycosylation sites. At the 3' end of the
coding region, a sequence encoding the tetrapeptide Lys-
Asp-Glu-Leu (KDEL) is observed. This sequence has been
found in proteins localized to the endoplasmic reticulum
(32-34). Murine ERp99, a protein that closely resembles
gp96, also has a C-terminal KDEL sequence (30) and is a
major component of the endoplasmic reticulum. Despite the
presence of a C-terminal KDEL sequence, the presence of
gp96 on the cell surface has been demonstrated by a number
of criteria: (i) immunoprecipitation of gp96 from surface
radioiodinated tumor cells; (ii) detection of gp96 on the cell
surface by erythrocyte rosetting on live cells; and (iii) isola-
tion of gp96 from purified plasma membranes (13). Presum-
ably, a fraction ofgp96 makes its way to the cell surface either
through the continuity of endoplasmic reticulum membrane
with the plasma membrane or by a specific mechanism that
modulates the influence of the KDEL sequence. Some nor-
mally secreted proteins-e.g., rat growth hormone and a
subunit of chorionic gonadotropin-are not retained in the
endoplasmic reticulum in spite ofthe addition of a C-terminal
KDEL sequence, supporting the notion that KDEL-
mediated endoplasmic reticular retention of gp96 is not ab-
solute (35).
The 5' untranslated, coding, and 3' untranslated regions of
murine and human gp96, grp94 (29), mouse ERp99/
endoplasmin (30), and chicken hsplO8 (27) show a high
degree of homology. These observations indicate that gp96,
grp94, and ERp99 are identical or belong to an extended
family of closely related molecules. The sequence of the
human grp94 promoter has been published (29) and is iden-
tical to the sequence of the human gp% promoter region
except for differences in 11 G and C residues, indicating that
gp96 and grp94 are either distinct genes or alleles of the same
gene. The complete sequence of the coding region of human
grp94 has not been published; hence, the precise degree of
homology between this gene and gp96 is not known. A cDNA
clone for a human hsplO8, a glycoprotein biochemically
indistinguishable from grp94, has recently been reported (36).
Human hsplO8 is 97% (nucleotide level) and 94% (amino acid
level) homologous to chicken hsplO8. In contrast, human
gp96 is 81% (nucleotide level) and 89% (amino acid level)
homologous to chicken hsplO8. In view of the fact that
complete sequence data on human hsplO8 are unavailable, it
is difficult to formally resolve whether these proteins are
identical, closely related, or represent different alleles.
The possibility that stress-induced proteins play an impor-
tant role in immune response in infectious and other diseases
has recently attracted considerable attention. Humoral and
cellular responses to several stress proteins have been de-
tected in animals and humans infected with bacterial and
parasitic agents (37, 38). In most cases, origin of the immu-
nogenic stimulus has not been defined: is the immune re-
sponse elicited by stress proteins of the infectious agent or
the host? Because of the highly conserved nature of stress
proteins (39), this is not an easy question to answer. Another
unresolved issue is the role of stress proteins in disease
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development: is the immunity to stress proteins protective,
injurious, or merely a by-product of the host immune re-
sponse to disease? These questions are also relevant to
finding antibodies and/or T cells to stress proteins in patients
with immune diseases such as rheumatoid arthritis (37, 38).
With regard to immune response to cancer, the work of
Ullrich et al. (40) raised the possibility that heat shock
proteins may be recognized as tumor antigens eliciting pro-
tective immunity. These investigators isolated 84/86-kDa
molecules from chemically induced tumors that induce spe-
cific resistance to tumor challenge. The p84/86 antigens
belong to the hsp90 family (28, 40), rather than the hsplO0
family as in the case of gp96 molecules (this paper). In
addition, immunity against murine melanomas (41) and a rat
histiocytoma (G. Deshpandd and A. Khar, personal commu-
nication) can be elicited by serum albumin-like proteins;
while albumin is expressed constitutively in adult life, it is
inducible by heat shock in fetal tissues (42). Furthermore,
immunogenicity of Ha-ras-transfected fetal rat fibroblasts
has been correlated with the presence on the cell surface of
a hsp70-related protein (43).
A key question is whether gp96 and these other stress
protein-related antigens are tumor antigens per se or whether
they serve as carriers for other immunogenic moieties. If, in
fact, the tumor-specific immunogenicity of gp96 and p84/86
resides in the primary structure, then point mutations, dele-
tions, or insertions could account for the extensive diversity
of chemically induced tumors. Consequent changes in the
encoded gp96 polypeptide could be recognized as antigenic
determinants following normal antigen presentation path-
ways. If, on the other hand, gp96 or other stress proteins
serve as carriers or presenting molecules for other immuno-
genic moieties, the association of peptides with class I and
class II antigens of the major histocompatibility complex is a
clear precedent (44-46). The ability of stress proteins to bind
to a number of different molecules is consistent with this
possibility (see ref. 47).
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